Chemotherapeutic drugs - More really is not better

Nature Medicine

Volumn 6, Issue 5, 2000, Pages 500-502

  Fidler, Isaiah J ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; VASCULOTROPIN RECEPTOR; VINBLASTINE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER INVASION; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; MAXIMUM PERMISSIBLE DOSE; METASTASIS; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR EMBOLISM; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; ENDOTHELIUM, VASCULAR; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034105964     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/74969     Document Type: Short Survey

References (18)

1. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889).
2. Fidler, I.J. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 50, 6130-6138 (1990).
3. Fidler, I.J. & Kripke, M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197, 893-895 (1977).
4. Fidler, I.J. Modulation of the organ microenvironment for the treatment of cancer metastasis. J. Natl. Cancer Inst. 84, 1588-1592 (1995).
5. Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
6. Klement, G. et al. Chronically sustained regressions of human tumor xenografts in the absence of overt toxicity by continuous low-dose vinblastine and anti-VEGF receptor-2 antibody therapy. J. Clin. Invest. 105, R15-R24 (2000).
7. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1, 27-31 (1995).
8. Benjamin, L.E. & Keshet, E. Conditioned switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 84, 8761-8766 (1997).
9. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
10. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
11. Yoneda, J. et al. Angiogenesis and growth of murine colon carcinoma are dependent on infiltrating leukocytes. Cancer Biother. Radiopharm. 14, 221-230 (1999).
12. Folkman, M.J. Angiogenic zip code. Nature Biotech. 17, 749-753 (1999).
13. Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366 (1996).
14. Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380 (1998).
15. Auerbach, W. & Auerbach, R. Angiogenesis inhibition: a review. Pharmacol. Ther. 63, 265-311 (1994).
16. Baker, C.H., Bruns, C.J., Fan, D., Killion, J.J. & Fidler, I.J. Differential effects of angiostatin (K1-4) and K5 on cultured endothelial cells of different origin. Proc. Amer. Assoc. Cancer Res. 41, 308 (2000).
17. Hidalgo, M. et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer, J. Clin. Oncol. 17, 585-592 (1999).
18. Ezekowitz, R.A.B., Mulliken, J.B. & Folkman, J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326, 1456-1463 (1992).